Not actual patients.

Padcev (enfortumab vedotin-ejfv)

For adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter, or urethra) that has spread or cannot be removed by surgery

We Choose What's Next

For adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter, or urethra) that has spread or cannot be removed by surgery

We Choose What's Next

Not actual patients.



IMPORTANT SAFETY INFORMATION

Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:

are currently experiencing numbness or tingling in your hands or feet

have a history of high blood sugar or diabetes

are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.

are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV.

Females who are able to become
pregnant:

Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.

You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.

Males with a female sexual partner
who is able to become pregnant:

If your female partner is pregnant, PADCEV can harm the unborn baby.

You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will you receive PADCEV?

PADCEV will be given to you by intravenous (IV) infusion into your vein over 30 minutes.

You will receive your PADCEV over periods of time called cycles.

- Each PADCEV cycle is 28 days.

- You will receive PADCEV on days 1, 8 and 15 of every cycle.

Your healthcare provider will decide how many treatment cycles you need.

Your healthcare provider may do blood tests regularly during treatment with PADCEV.

What are the possible side effects of PADCEV?
PADCEV may cause serious side effects including:

Skin Reactions. Severe skin reactions have happened after treatment with PADCEV, in some cases causing death. Most severe skin reactions occurred during the first cycle (28 days) of treatment but may happen later. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction: target lesions (skin reactions that look like rings), rash or itching that continues to get worse; blistering or peeling of the skin; painful sores or ulcers in mouth or nose, throat, or genital area; fever or flu-like symptoms; or swollen lymph nodes.

High Blood Sugar (hyperglycemia). You can develop high blood sugar during treatment with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.

Peripheral neuropathy. You may develop nerve problems called peripheral neuropathy during treatment with PADCEV. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet, or muscle weakness.

Eye problems. You can develop certain eye problems during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes or blurred vision. You may use artificial tear substitutes to help prevent or treat dry eyes.

Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, or discomfort at the infusion site.

The most common side effects of PADCEV
include:

tiredness (fatigue)

numbness or tingling in your hands or feet, or muscle weakness

decreased appetite

rash

hair loss

nausea

diarrhea

change in sense of taste

dry eyes

dry skin

If you have certain side effects, your healthcare provider may decrease your dose or stop your treatment with PADCEV for a period of time (temporarily) or completely.

PADCEV may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of PADCEV.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.



WHAT IS PADCEV®?

PADCEV (enfortumab vedotin-ejfv) is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used if you have:

received an immunotherapy medicine and

also received a chemotherapy-containing platinum medicine.

It is not known if PADCEV is safe and effective in children.

PADCEV was FDA-approved based on a clinical study that measured how many patients had a tumor response. There is another study with PADCEV to confirm the clinical benefit.

Please click here for full Prescribing Information.



IMPORTANT SAFETY INFORMATION

Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:

are currently experiencing numbness or tingling in your hands or feet

have a history of high blood sugar or diabetes

are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.

are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV.

Females who are able to become
pregnant:

Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.

You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.

Males with a female sexual partner
who is able to become pregnant:

If your female partner is pregnant, PADCEV can harm the unborn baby.

You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will you receive PADCEV?

PADCEV will be given to you by intravenous (IV) infusion into your vein over 30 minutes.

You will receive your PADCEV over periods of time called cycles.

- Each PADCEV cycle is 28 days.

- You will receive PADCEV on days 1, 8 and 15 of every cycle.

Your healthcare provider will decide how many treatment cycles you need.

Your healthcare provider may do blood tests regularly during treatment with PADCEV.

What are the possible side effects of PADCEV?
PADCEV may cause serious side effects including:

Skin Reactions. Severe skin reactions have happened after treatment with PADCEV, in some cases causing death. Most severe skin reactions occurred during the first cycle (28 days) of treatment but may happen later. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction: target lesions (skin reactions that look like rings), rash or itching that continues to get worse; blistering or peeling of the skin; painful sores or ulcers in mouth or nose, throat, or genital area; fever or flu-like symptoms; or swollen lymph nodes.

High Blood Sugar (hyperglycemia). You can develop high blood sugar during treatment with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.

Peripheral neuropathy. You may develop nerve problems called peripheral neuropathy during treatment with PADCEV. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet, or muscle weakness.

Eye problems. You can develop certain eye problems during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes or blurred vision. You may use artificial tear substitutes to help prevent or treat dry eyes.

Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, or discomfort at the infusion site.

The most common side effects of PADCEV
include:

tiredness (fatigue)

numbness or tingling in your hands or feet, or muscle weakness

decreased appetite

rash

hair loss

nausea

diarrhea

change in sense of taste

dry eyes

dry skin

If you have certain side effects, your healthcare provider may decrease your dose or stop your treatment with PADCEV for a period of time (temporarily) or completely.

PADCEV may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of PADCEV.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.



WHAT IS PADCEV®?

PADCEV (enfortumab vedotin-ejfv) is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used if you have:

received an immunotherapy medicine and

also received a chemotherapy-containing platinum medicine.

It is not known if PADCEV is safe and effective in children.

PADCEV was FDA-approved based on a clinical study that measured how many patients had a tumor response. There is another study with PADCEV to confirm the clinical benefit.

Please click here for full Prescribing Information.



IMPORTANT SAFETY INFORMATION

Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:

are currently experiencing numbness or tingling in your hands or feet

have a history of high blood sugar or diabetes

are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.

are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV.

Females who are able to become
pregnant:

Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.

You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.

Males with a female sexual partner
who is able to become pregnant:

If your female partner is pregnant, PADCEV can harm the unborn baby.

You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will you receive PADCEV?

PADCEV will be given to you by intravenous (IV) infusion into your vein over 30 minutes.

You will receive your PADCEV over periods of time called cycles.

- Each PADCEV cycle is 28 days.

- You will receive PADCEV on days 1, 8 and 15 of every cycle.

Your healthcare provider will decide how many treatment cycles you need.

Your healthcare provider may do blood tests regularly during treatment with PADCEV.

What are the possible side effects of PADCEV?
PADCEV may cause serious side effects including:

Skin Reactions. Severe skin reactions have happened after treatment with PADCEV, in some cases causing death. Most severe skin reactions occurred during the first cycle (28 days) of treatment but may happen later. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction: target lesions (skin reactions that look like rings), rash or itching that continues to get worse; blistering or peeling of the skin; painful sores or ulcers in mouth or nose, throat, or genital area; fever or flu-like symptoms; or swollen lymph nodes.

High Blood Sugar (hyperglycemia). You can develop high blood sugar during treatment with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.

Peripheral neuropathy. You may develop nerve problems called peripheral neuropathy during treatment with PADCEV. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet, or muscle weakness.

Eye problems. You can develop certain eye problems during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes or blurred vision. You may use artificial tear substitutes to help prevent or treat dry eyes.

Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, or discomfort at the infusion site.

The most common side effects of PADCEV
include:

tiredness (fatigue)

numbness or tingling in your hands or feet, or muscle weakness

decreased appetite

rash

hair loss

nausea

diarrhea

change in sense of taste

dry eyes

dry skin

If you have certain side effects, your healthcare provider may decrease your dose or stop your treatment with PADCEV for a period of time (temporarily) or completely.

PADCEV may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of PADCEV.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.



WHAT IS PADCEV®?

PADCEV (enfortumab vedotin-ejfv) is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used if you have:

received an immunotherapy medicine and

also received a chemotherapy-containing platinum medicine.

It is not known if PADCEV is safe and effective in children.

PADCEV was FDA-approved based on a clinical study that measured how many patients had a tumor response. There is another study with PADCEV to confirm the clinical benefit.

Please click here for full Prescribing Information.

© 2021 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-0448-PM 04/21
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.


© 2021 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-0448-PM 04/21
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.

© 2021 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-0448-PM 04/21
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.


© 2021 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-0448-PM 04/21
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.